WESTBROOK, Maine, July 17, 2017 /PRNewswire/ -- IDEXX
Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary
diagnostics, veterinary practice software and water microbiology
testing, today announced the unanimous election of Stuart M. Essig as a member of the Company's
Board of Directors, effective July 12,
2017. In connection with Dr. Essig's election, the Board
also increased its size from 8 to 9 members, effective July 12, 2017.
Dr. Essig has been the Chairman of the Board of Directors of
Integra LifeSciences Holdings Corporation since 2012, and he served
as Integra's Chief Executive Officer from 1997 until 2012, building
Integra into a leading global surgical products company. He has
also served since 2012 as Managing Director of Prettybrook Partners
LLC, a private investment firm focused on the healthcare industry.
In addition to Integra, Dr. Essig currently serves on the Boards of
Directors of SeaSpine Holdings Corporation and Owens & Minor,
Inc. and is the Chairman of the Board of Directors of Breg, Inc., a
private company offering nonsurgical orthopedic care products and
solutions. He previously served on the Boards of Directors of St.
Jude Medical Corporation from 1999 to 2017, prior to its sale to
Abbott Corporation, and Zimmer Biomet Holdings, Inc. from 2005 to
2008.
"We are excited to welcome Stuart to our Board of Directors,"
said Jonathan Ayers, the Company's
Chairman and Chief Executive Officer. "Stuart brings extensive
executive management experience and deep strategic expertise in the
global healthcare industry, and he has served on the boards of
several private and public companies. Stuart's perspective and
insight will further strengthen our Board's already broad and
diverse capabilities and experiences and be extremely valuable to
IDEXX as we continue our growth trajectory as a global leader in
pet healthcare innovation."
"IDEXX's business model of enduring growth through innovation in
a highly attractive, expanding industry has yielded strong
returns," said Dr. Essig. "I look forward to working with my fellow
Board members to support extending IDEXX's successful track record
of strong organic growth and building exceptional long-term value
for our shareholders."
Before joining Integra in 1997, Dr. Essig was a managing
director in mergers and acquisitions for Goldman, Sachs and Co.,
specializing in the medical device, pharmaceutical and
biotechnology sectors. Dr. Essig has also served on the executive
committee, nominating and governance committee, and as treasurer of
ADVAMED, the Advanced Medical Technology Association. Dr. Essig
holds an A.B. from Princeton University
and an M.B.A. and Ph.D. in financial economics from the
University of Chicago.
About IDEXX Laboratories
IDEXX Laboratories,
Inc. is a member of the S&P 500® Index and is a
leader in pet healthcare innovation, serving practicing
veterinarians around the world with a broad range of diagnostic and
information technology-based products and services. IDEXX products
enhance the ability of veterinarians to provide advanced medical
care, improve staff efficiency, and build more economically
successful practices. IDEXX is also a worldwide leader in providing
livestock and poultry diagnostic tests and tests for the quality
and safety of water and milk. Headquartered in Maine, IDEXX employs more than 7,000 people
and offers products to customers in over 175 countries. For more
information about IDEXX, visit: www.idexx.com.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be
identified by the use of words such as "expects," "may,"
"anticipates," "intends," "would," "will," "plans," "believes,"
"estimates," "should," and similar words and expressions. These
forward-looking statements are based on management's current
expectations and beliefs, as well as a number of assumptions
concerning future events. These statements are subject to risks,
uncertainties, assumptions and other important factors. Readers are
cautioned not to put undue reliance on such forward-looking
statements because actual results may vary materially from those
expressed or implied. The reports filed by the Company pursuant to
United States securities laws
contain discussions of these risks and uncertainties. The Company
assumes no obligation to, and expressly disclaims any obligation
to, update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Readers are
advised to review the Company's filings with the United States
Securities and Exchange Commission (which are available from the
SEC's EDGAR database at www.sec.gov/, at various SEC reference
facilities in the United States
and via the Company's website at www.idexx.com).
Contact:
Investor Relations:
Kerry
Bennett
207-556-8155
View original content with
multimedia:http://www.prnewswire.com/news-releases/idexx-laboratories-elects-stuart-m-essig-to-board-of-directors-300489267.html
SOURCE IDEXX Laboratories, Inc.